Reappraisal of European guidelines on hypertension management: a European Society of Hypertension LY2874455 datasheet Task Force document. J Hypertens. 2009;27:2121–58.PubMedCrossRef 15. Coca A. Evolucion del control de la hipertension

arterial en atencion primaria en Espana. Resultados del estudio Controlpress 2003. Hipertension. 2005;22:5–14.CrossRef 16. Sociedade Portuguesa de Hipertensao. Prevalencia da hipertensao arterial e consumo de sal em Portugal. Rev Port Hipertensao e Risco Cardiovascular. 2013;34:8–9. 17. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al. Differences in glucose tolerance between Selleckchem GSK461364 Fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592–7.PubMedCrossRef 18. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk

patients. N Engl J Med. 2008;359:2417–28.PubMedCrossRef 19. Matsui Y, Eguchi K, O’Rourke MF, Ishikawa J, Miyashita H, Shimada K, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54:716–23.PubMedCrossRef 20. Puig JG, Calvo C, Luurila O, Luurila H, Sulosaari S, Strandberg A, et al. Lercanidipine, enalapril and their combination in the treatment this website of elderly hypertensive patients: placebo-controlled,

randomized, crossover study with four ABPM. J Hum Hypertens. 2007;21:917–24.PubMedCrossRef 21. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs. 2007;67:95–106.PubMedCrossRef 22. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.PubMedCrossRef 23. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials. J Hypertens. 2011;29:1270–80.PubMedCrossRef 24. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin MTMR9 system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128–35.PubMedCrossRef 25. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182–7.PubMedCrossRef 26. Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens. 2011;13:667–75.